Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! Please be sure to document all clinical activities daily.
For emergent treatment of severe complicated malaria, the CDC is currently recommending artesunate. This agent is not yet approved by the FDA in the US, but is available from the CDC on an emergency basis if needed.
Updated: January 2019 (IV quiNIDine gluconate manufacturer discontinued)
CDC Recommendation as of January 2019:
For emergent treatment of severe complicated malaria, the CDC is currently recommending artesunate. This agent is not yet approved by the FDA in the US, but is available from the CDC on an emergency basis if needed.
Updated: January 2019 (IV quiNIDine gluconate manufacturer discontinued)